Short‐acting insulin analogues vs regular human insulin: All‐cause mortality
- Population
- Not specified
- Intervention
- Short‐acting insulin analogues
- Comparison
- regular human insulin
- Outcome
- All‐cause mortality
Reviews word the same question differently. Two decision models (TypeSafe's Jev and Liquid AI's d1) judged each wording of the population, intervention, comparator and outcome against the others, and rows count as this question only when both agree on all four. Timing, setting and subgroup never split a question: they are shown on each row.
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
How each review answered it
Include earlier review versions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short‐acting insulin analogues vs regular human insulin All‐cause mortality (N) Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2… (2018) · Cochrane | Peto OR 1.66 [0.41, 6.64] | 6 studies · 2519 participants | Moderate |
Short‐acting insulin analogues vs regular human insulin All‐cause mortality Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus (2016) · Cochrane | no estimate extracted | NR | No studies |
Trials and studies behind the answers
The primary studies that full-text reviews tie to these outcomes. Reviews from the Summary of Findings tier list no included studies here, and trials have not yet been matched to questions on their own, so this list is incomplete.